The UK Competition Authority cancels its phase II investigation following an abandon merger in the DNA sequencing systems market (Illumina / PacBio)

KEYWORDS
Reference

UK Competition Authority (London), Illumina / PacBio, Press Release, 3 January 2020

Illumina/PacBio abandon merger* Illumina has abandoned its anticipated $1.2 billion takeover of PacBio after an in-depth CMA merger probe highlighted serious competition concerns. The Competition and Markets Authority (CMA) has therefore today

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

UK Competition Authority, The UK Competition Authority cancels its phase II investigation following an abandon merger in the DNA sequencing systems market (Illumina / PacBio), 3 January 2020, e-Competitions Pharma & Mergers, Art. N° 92959

Visites 342

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues